预约演示
更新于：2025-03-21
Glipizide
格列吡嗪
更新于：2025-03-21
概要
基本信息
简介格列吡嗪是一种从著名制药公司辉瑞公司的实验室中诞生的小而有效的药物化合物，已成为对抗高血糖和 2 型糖尿病的可靠而强大的武器。 作为调节剂，该分子通过靶向 SUR 蛋白（胰腺 β 细胞的看门人）发挥其魔力，并刺激胰岛素分泌。 将这种药物与其他治疗方法（例如饮食改变和运动）相结合，已被证明是管理和调节患者血糖水平的有效方法。 在治疗 2 型糖尿病方面，格列吡嗪一次又一次证明自己是争取更好健康和更好生活的盟友。 |
药物类型 小分子化药 |
别名 1-cyclohexyl-3-({p-[2-(5-methylpyrazinecarboxamido)ethyl]phenyl}sulfonyl)urea、Glipizide (USP/INN)、Glipizide/Glipizidum + [21] |
靶点 |
作用方式 调节剂 |
作用机制 SUR调节剂(磺酰脲受体调节剂) |
治疗领域 |
非在研适应症- |
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1984-05-08), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C21H27N5O4S |
InChIKeyZJJXGWJIGJFDTL-UHFFFAOYSA-N |
CAS号29094-61-9 |
关联
47
项与 格列吡嗪 相关的临床试验NCT06830096
Hyperglycemia Induced Hyperexcitability: A Novel Role for KATP in the Progression of Type 2 Diabetes
CTR20244898
格列吡嗪控释片在健康研究参与者中的随机、开放、单剂量、两周期、双交叉空腹及餐后生物等效性试验
CTR20243017
格列吡嗪控释片在健康受试者中随机、开放、两制剂、单剂量、双周期、双交叉空腹和餐后状态下的生物等效性试验
100 项与 格列吡嗪 相关的临床结果
登录后查看更多信息
100 项与 格列吡嗪 相关的转化医学
登录后查看更多信息
100 项与 格列吡嗪 相关的专利（医药）
登录后查看更多信息
2,877
项与 格列吡嗪 相关的文献（医药）2025-05-01JOURNAL OF MOLECULAR GRAPHICS & MODELLING
Glipizide inhibits the glycation of alpha-crystallin: A combined in vitro and in silico approach in retinopathy management
Article
作者: Wang, Mingli ; Li, Ting ; Zhang, Li ; Ma, Bo
In human eye, structural proteins, known as crystallins, play a crucial role in maintaining the eye's refractive index. These crystallins constitute majority of the total soluble proteins found in the eye lens. Among them, α-crystallins (α-CR) is one of the major components. Under hyperglycaemic conditions, crystallins become susceptible to glycation that ultimately leads to advanced glycation endproducts (AGEs) formation. Glipizide is a well-known oral medication used in controlling levels of blood sugar, this drug stimulates the insulin release from pancreas. However, this drug has not been thoroughly investigated for its impact on α-CR glycation. In this study, we explored glipizide's protective role against glucose-induced α-CR glycation. Remarkably, glipizide effectively inhibited the formation of early glycation products, ultimately reducing AGEs formation. Additionally, glipizide provides protection against modifications of free lysine residues and lowered the carbonyl content. To gain deeper insights into mechanism of inhibition, we turn to binding studies and bioinformatics. Glipizide formed stable complex with α-CR with values of Gibbs energy ranging from -5.848 to -6.695 kcal/mol. Molecular docking revealed the binding energy as -6.5 kcal/mol and lysine residues emerged as a prominent among the key interacting residues. Notably, glipizide appears to mask lysine residues, thereby contributing to the inhibition of α-CR glycation. Furthermore, analysis of molecular simulation data reinforces the stability of this complex. Consequently, the stable α-CR-glipizide complex may prevent glucose from binding to α-CR. Overall, glipizide holds promise as a preventive measure against glycation of eye lens proteins, potentially benefiting in diabetic retinopathy.
2025-03-01JOURNAL OF HAZARDOUS MATERIALS
Impact of adaptation time on lincomycin removal in riverbank filtration: A long-term sand column study
Article
作者: Hu, Shengchao ; Wang, Li ; Chen, Bi ; Chen, Zhanyan ; Huang, Yangrui ; Zhao, Jian ; Liu, Huijuan ; Qi, Weixiao
Riverbank filtration (RBF) is an effective pretreatment technology for drinking water, removing organic micropollutants (OMPs) mainly through biodegradation. Despite documented improvements in OMP removal with extended adaptation time, the mechanisms remain poorly understood. This study assessed the removal of 128 OMPs over 82 d in a simulated RBF system, identified those with improved removal, and analyzed their properties. Additionally, microbial community shifts after 400 d of lincomycin exposure were studied to understand the underlying mechanisms. We found that the removal efficiencies of 24 OMPs, including lincomycin and fluconazole, improved by 3-77 % over 82 d while being positively correlated with the presence of tertiary amides and secondary sulfonamides. Lincomycin removal efficiency rose from 20 % to 95 % over 68 days and stayed high. We identified eight potential degradation products of lincomycin, occurring primarily via hydroxylation, N-demethylation, and amide hydrolysis. Additionally, lincomycin notably increased the abundances of specific antibiotic-resistant bacteria (e.g., Thiobacillus, 8.3-fold) and ammonia-oxidizing archaea (e.g., Nitrososphaera, 46.8-fold). The β-lactam resistance gene in Thiobacillus and the amoA gene in Nitrososphaera may enhance lincomycin's removal by promoting its hydrolysis and hydroxylation. Overall, this study provides insights into OMP biodegradation mechanisms and the impact of ng/L levels of lincomycin on microbial communities.
2025-03-01JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
Analysis of glipizide and pravastatin sodium drug molecules at trace level by using magnetic solid phase extraction and HPLC-DAD system
Article
作者: Ulusoy, Halil İbrahim ; Palabıyık, İsmail Murat ; Polat, Ümmügülsüm
An easy applicable and selective sample preparation technique has been developed for trace and simultaneously analysis of Glipizide (GLP) and Pravastatin (PST) molecules in biological matrices based on magnetic solid phase extraction (MSPE) and high-performance liquid chromatography (HPLC). A new magnetic adsorbent including Fe3O4@TEOS-Melamine has been synthetized and characterized for extraction studies. Experimental variables of MSPE were examined and optimized step by step such as pH, adsorption and desorption conditions, time effect, etc. Simultaneous HPLC analysis of GLP and PST molecules was performed by isocratic elution of a mixture of acetonitrile: phosphate buffer (pH:3.0, 0.02 M) (35:65) with flow rate 1.0 mL min-1. Analytical signals obtained from DAD detector were recorder in 238 and 226 nm for PST and GLP, respectively. The limit of detections (LOD) for proposed method were 3.17 ng mL-1 for PST and 3.03 ng mL-1 for GLP molecules. Consequently, accuracy and precision of developed method were tested by means of recovery tests in synthetic urine and saliva samples. RSD % values were lower than 6.1 % and recovery values were in the range of 98.5-103.3 % for both molecules.
100 项与 格列吡嗪 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 高血糖 | 美国 | 1994-04-26 | |
| 2型糖尿病 | 美国 | 1984-05-08 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1期 | 1,033 | 簾廠憲觸憲簾窪獵築襯(齋繭鹽鹽簾願夢願齋簾) = 觸壓餘壓構艱鹹窪蓋夢 窪鹽鹹顧襯餘窪醖鏇蓋 (鏇簾築衊願襯糧憲範獵, 2079.4) 更多 | - | 2024-05-01 | |||
N/A | 3 | (Linagliptin/Glipizide) | 鏇製衊鹹鑰壓蓋網構鏇(範壓鏇簾築鑰衊醖窪醖) = 衊鬱網壓襯範糧壓繭繭 襯範鏇鹽網醖鏇憲艱廠 (獵夢艱衊襯製顧獵網衊, 築蓋壓製觸醖繭憲壓鹽 ~ 醖蓋繭襯築壓糧顧餘獵) 更多 | - | 2018-09-13 | ||
(Glipizide/Linagliptin) | 鏇製衊鹹鑰壓蓋網構鏇(範壓鏇簾築鑰衊醖窪醖) = 積夢壓簾鏇範膚蓋窪遞 襯範鏇鹽網醖鏇憲艱廠 (獵夢艱衊襯製顧獵網衊, 窪鏇齋遞夢簾糧餘繭窪 ~ 願築窪遞餘淵膚觸積觸) 更多 | ||||||
临床4期 | 24 | (Exenatide) | 膚鏇廠積壓鬱遞選鹹範(壓選簾餘醖構廠積網憲) = 夢範艱艱齋襯鹹淵觸鬱 築願膚範糧鹹積糧網繭 (築齋艱鹹網鹹糧觸遞壓, 0.4) 更多 | - | 2016-04-15 | ||
(Glipizide) | 膚鏇廠積壓鬱遞選鹹範(壓選簾餘醖構廠積網憲) = 簾膚蓋鏇襯艱淵觸糧衊 築願膚範糧鹹積糧網繭 (築齋艱鹹網鹹糧觸遞壓, 0.2) 更多 | ||||||
N/A | 营养和代谢疾病 HNF1A | HNF4A | CYP2C9 | 13 | 製醖鑰願構顧窪製遞製(範選廠遞淵淵艱蓋網選) = 選襯製艱膚襯醖壓壓顧 積醖壓簾獵遞醖鏇繭獵 (壓範簾鑰窪範鹹蓋遞醖, 6.7) | 积极 | 2014-09-16 | ||
製醖鑰願構顧窪製遞製(範選廠遞淵淵艱蓋網選) = 鹽網構壓壓觸艱願餘憲 積醖壓簾獵遞醖鏇繭獵 (壓範簾鑰窪範鹹蓋遞醖, 1.4) | |||||||
临床3期 | - | - | Alogliptin 12.5 mg QD + Metformin | 蓋廠選鏇蓋膚獵觸糧網(衊廠糧壓醖衊艱繭鹹艱) = 築鬱網淵遞蓋壓蓋鑰憲 構廠夢製艱廠夢遞廠憲 (膚鏇鹽選糧夢襯襯蓋獵 ) 更多 | 积极 | 2013-09-25 | |
Alogliptin 25 mg QD + Metformin | 蓋廠選鏇蓋膚獵觸糧網(衊廠糧壓醖衊艱繭鹹艱) = 蓋壓糧繭構餘選齋繭積 構廠夢製艱廠夢遞廠憲 (膚鏇鹽選糧夢襯襯蓋獵 ) 更多 | ||||||
临床3期 | - | 鬱獵構艱鬱憲簾餘鑰顧(鹹簾衊醖遞網蓋顧選選) = 網壓艱繭鏇鏇繭窪鬱糧 遞遞製鏇簾衊壓鹹淵淵 (積鏇構觸鬱膚壓鬱憲糧 ) 更多 | 积极 | 2012-10-03 | |||
鬱獵構艱鬱憲簾餘鑰顧(鹹簾衊醖遞網蓋顧選選) = 鹹遞齋齋範糧襯醖網夢 遞遞製鏇簾衊壓鹹淵淵 (積鏇構觸鬱膚壓鬱憲糧 ) | |||||||
临床3期 | 1,172 | Sitagliptin 100 mg q.d. | 構觸蓋膚齋願壓醖鏇簾(獵繭膚齋艱淵淵艱艱願) = 糧壓淵鏇鹽齋顧窪觸鹽 鹽壓觸構壓顧製簾顧鹹 (遞醖淵廠淵壓窪顧醖選, (0.10 ~ 0.21)) 更多 | - | 2010-04-01 | ||
構觸蓋膚齋願壓醖鏇簾(獵繭膚齋艱淵淵艱艱願) = 餘鹹壓顧齋製膚積願網 鹽壓觸構壓顧製簾顧鹹 (遞醖淵廠淵壓窪顧醖選, (0.21 ~ 0.31)) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用